Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
X
X

blog
January 13, 2020 by Charlie Silver

The 2019 Nature Method of the Year will change the world, in 2020 and beyond

2019 was a monumental year for single-cell genomics: from enabling custom DNA panels with AI-driven technology, to partnering with key businesses in the drug development ecosystem, to pioneering research revealing the mechanisms used by rogue cancer cells to evade targeted therapies, the Tapestri Platform has opened up high-impact applications for customers around the world. 

 

Perhaps the most important advancement in Mission Bio’s pursuit for improved cancer therapies is enabling industry-first capability in single-cell multimodal omics: simultaneous detection of DNA mutations and protein expression in a single experiment from the same cell. The ability to correlate the genotype and phenotype of cancer cells directly and without inference gives cancer researchers a transformative understanding of the disease, bringing them ever closer to more effective cures.

 

Nature has recognized single-cell multimodal omics as the Method of the Year and we are proud that the Tapestri Platform is enabling this for researchers around the world. With the leading platform for single-cell multimodal omics, Mission Bio is on a mission to enable the cancer research community to find cures for cancer.

 

Happy new year, and we look forward to seeing you in Marco Island.

 


blog
Mission Bio and Agilent Technologies Partner to Advance Precision Medicine
Darrin Crisitello
blog
MD Anderson Analyzes AML With Tapestri, Unveiling New Therapy Response Patterns
Charlie Silver
blog
How Stanford is Using Tapestri to Understand Cancer Relapse
Charlie Silver
blog
Today Marks Another Mission Bio Milestone Towards Beating Cancer by 2030
Charlie Silver
REQUEST QUOTE